FDA Approves Foundation Medicine Liquid Biopsy Test as CDx for Three Targeted Therapies
FoundationOne Liquid CDx can now be used as a companion diagnostic for therapies to treat advanced ovarian, breast, and non-small cell lung cancer.
Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Diagnostic Indications
The agency approved the test for use across solid tumors and with multiple companion diagnostic indications including one for prostate cancer and three for lung cancer.
Clovis, Myriad Genetics Working to Meet Post-Market Study Commitment for PARP Inhibitor
Myriad said it will submit a supplementary premarket approval application for its BRACAnalysis CDx, which the FDA originally approved in 2014.